[Nfbf-l] FW: Medical News] Treatment That SignificantlySlowsProgression Of Eye Damage In Persons With Type1 Diabetes -

[Kirk]

Elizabeth, This  is wonderful news! I thank you for forwarding this news to 
all of us. I am type 1 and have already had a transplant of both my pancreas 
and kidney respectfully. I have permanent damage to my retina's as well due 
to years of hypertension and my blood vessels bursting within my eyes until 
they got a point of permanent damage that cannot be reversed. I have been 
told that I could lose total vision if this damage continues as well. I will 
most definitely check further into this news and again, not just for myself, 
but for so many others like myself. You taking the time to forward this news 
for all to read is greatly appreciated!  Your friend n the cause, KirkHarmon
----- Original Message ----- 
From: "elizabeth McNally" <bethmac at bellsouth.net>
To: "'NFB of Florida Listserv'" <nfbf-l at nfbnet.org>
Sent: Sunday, July 12, 2009 4:42 PM
Subject: [Nfbf-l] FW: Medical News] Treatment That 
SignificantlySlowsProgression Of Eye Damage In Persons With Type1 Diabetes -


> Treatment That Significantly Slows Progression Of Eye Damage In Persons 
> With
> Type
> 1 Diabetes - University Of Minnesota
> Article Date: 03 Jul 2009 - 0:00 PDT
> University of Minnesota Medical School researcher Michael Mauer, M.D., has
> found a treatment that significantly slows the progression of eye injury 
> in
> people with type 1 diabetes , a common complication caused by this 
> disease.
> By administering an antihypertensive, medication commonly prescribed to
> treat high blood pressure, Mauer and colleagues were able to slow
> progression of diabetic eye damage in more than 65 percent of participants
> involved in the study.
> Diabetes is the primary cause of acquired blindness in adults and accounts
> for nearly half of all new cases of chronic kidney failure in the Unites
> States each year, and people living with the disease often struggle with
> these complications as it progresses.
> Previous studies of people with type 1 diabetes who were already 
> exhibiting
> symptoms of vision and kidney function loss showed that these types of
> antihypertensive medications slowed further function loss in the kidneys,
> but often could not prevent kidney failure.
> Mauer and colleagues were interested in testing whether or not they could
> delay diabetic kidney injury in participants who had normal blood pressure
> and had not yet shown signs of kidney disease at the beginning of the 
> study.
> Three groups of participants were observed over the course of five years.
> Two groups
> were administered one of two antihypertensive medications, losartan or
> enalapril, and the last group, a placebo. The results were unexpected, but
> conclusive.
> Mauer's
> study demonstrated that these drugs did not protect the participants'
> kidneys from
> damage or from losing function. However, participants who were 
> administered
> either enalapril or losartan experienced a significant slowing of the
> progression of diabetic eye injury, by 65 and 70 percent, respectively.
> "The secondary results of this study showed that people taking these
> antihypertensive medications experienced a substantially positive effect 
> in
> slowing diabetic eye injury,"
> said Mauer, professor of pediatrics and medicine in the Medical School.
> "Although
> neither medication delayed early kidney tissue injury or early loss of
> kidney function, the advantage to a study with negative findings such as
> this one is that physicians now know that this treatment is ineffective 
> for
> this purpose, and they can pursue other treatment options that may improve
> their patients' outcomes."
> Although the data does not support the use of these types of
> antihypertensives to prevent kidney damage in people living with diabetes,
> Mauer and colleagues find it reasonable for physicians to consider
> prescribing these classes of medication to people with type 1 diabetes in
> order to slow the onset and progression of diabetic eye disease. He notes,
> though, that this also poses several other unanswered questions such as at
> what age a person with diabetes should be prescribed this class of drug 
> and
> how long they should continue taking it.
> Mauer's study "Renal and Retinal Effects of Enalapril and Losartan in Type 
> 1
> Diabetes"
> is published in the July 2nd issue of
> The New England Journal of Medicine.
> An editorial accompanies the article.
> The study was supported by research grants from the National Institutes of
> Health (National Institute of Diabetes and Digestive and Kidney Diseases),
> Merck (in the United States), Merck Frosst (in Canada), and the Canadian
> Institutes of Health Research.
> Source:
> Nick Hanson
> University of Minnesota
>
> Checked by AVG - www.avg.com
> Version: 8.5.375 / Virus Database: 270.13.3/2216 - Release Date: 07/03/09
> 05:53:00
>
>
> _______________________________________________
> Nfbf-l mailing list
> Nfbf-l at nfbnet.org
> http://www.nfbnet.org/mailman/listinfo/nfbf-l_nfbnet.org
> To unsubscribe, change your list options or get your account info for 
> Nfbf-l:
> http://www.nfbnet.org/mailman/options/nfbf-l_nfbnet.org/kvharmon54%40gmail.com